EXCLUSIVE: From Taboo To Treatment In Germany’s Cannabis Landscape (CORRECTED)
Editor’s note: This story has been updated to correct the spelling of Anna-Sophia Kouparanis’ name.
Since the legalization of medical cannabis in Germany in 2017, the industry has faced notable challenges, chiefly the scarcity of physicians ready to prescribe these treatments.
Anna-Sophia Kouparanis, co-founder of the Bloomwell Group, has been pivotal in addressing this issue. Her innovative approach led to the development of a telemedicine subsidiary under Bloomwell, significantly broadening patient access to medical cannabis.
“The big bottleneck in the market was that we didn’t have enough doctors to actually prescribe medical cannabis to patients,” Kouparanis pointed out on Benzinga’s Cannabis Insider, highlighting the initial hurdles in patient treatment accessibility.
Introducing Groundbreaking Products
Bloomwell Group’s commitment to enhancing patient care through innovative products has set new standards in the German medical cannabis market. Kouparanis shared her excitement about launching Germany’s first medical cannabis vape pen, a significant stride towards diversifying treatment options.
This introduction represented a landmark achievement, offering patients an alternative method of consumption previously unavailable …